Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 13,301–13,400 of 15,747
Mokuda, S., Kawanishi, N., Kuroshima, S., Kono, J., Nakayama, H., Mieno, H., & Kawamoto, M. (2022) · Vaccine X · doi:10.1016/j.jvacx.2022.100173 · Cited by 1
“Bamlanivimab (LY-CoV555), an anti-RBD monoclonal antibody, was ineffective in hospitalized patients with COVID-19 but reduced the incidence of SARS-CoV-2 infections in residents and staff of skilled nursing and assisted living facilities [10,11].”
InfluentialTeffera, Z. H., Belay, W. Y., Tegegne, B. A., Belew, H., Adugna, A., Laykun, Y., Tefera, S., Muche, Y., Melkamu, A., Amare, G. A., et al. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-11717-5 · Cited by 1
Zhang, A. S., Berreta, R. S., Osorio, C., & Daniels, A. H. (2021) · Spinal Cord Series and Cases · doi:10.1038/s41394-021-00465-8 · Cited by 1
“1%, respectively, with an additional reduction of almost 100% in cases of severe COVID-19 [16, 17].”
Steffes, V. M., Zhang, Z., Ewert, K. K., & Safinya, C. R. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.09.552538 · Cited by 1
Are we coming out from the COVID ‐19 pandemic?
Leung, C. C., & Lee, A. C. (2022) · Respirology · doi:10.1111/resp.14403
“The development of updated vaccines well-matched to the circulating strains is likely to help protect against both infection and severe disease.(15) But this is not enough—a global mechanism to allow the rapid distribution of updated COVID-19 vaccines against evolving virus variants is also critical.”
BackgroundResearch progress on the vaccine of Epstein-Barr virus
Jiang, Z., XianShu, T. I. A. N., Chu, X. I. E., Zhong, Q., Cong, S. U. N., & Zeng, M. (2024) · Scientia Sinica Vitae · doi:10.1360/ssv-2024-0179 · Cited by 1
Liu, Y., Zhang, W., Sun, M., et al. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-03333-x · Cited by 1
Alves, K., Kotloff, K., McClelland, R. S., Hammershaimb, E. A., Kouassi, A., Plested, J. S., Kalkeri, R., Zhu, M., Cloney-Clark, S., Cai, Z., et al. (2025) · Vaccine X · doi:10.1016/j.jvacx.2025.100728 · Cited by 1
Precup, C. V., Mateescu, D.-M., Enache, A., Buhaș, C. L., & Mureșan, C.-O. (2026) · Microorganisms · doi:10.3390/microorganisms14061256
“Vaccination has substantially reduced acute COVID-19 severity [14] and attenuated, though not eliminated, the risk of long COVID after breakthrough infection [15]; nonetheless, cardiovascular sequelae have been documented up to two years post-infection in large cohort analyses [16].”
Emary, K. R. W., Naudé, R. T. W., Stewart, A., et al. (2025) · BMJ Public Health · doi:10.1136/bmjph-2025-003096
Cooper, D. K., Sobolik, J. S., Kovačević, J. J., Rock, C. M., Sajewski, E. T., Guest, J. L., Lopman, B. A., Jaykus, L., & León, J. S. (2022) · medRxiv · doi:10.1101/2022.04.06.22273125
Self-citationCOVID-19 Vaccine Manufacturing Processes: Making the Molecules to Solve the Pandemic
Romine, J. A. S., Kolodziej, S. A., Vetter, T., & Dux, M. P. (2024) · Springer eBooks · doi:10.1007/978-3-031-62007-2_8
Binkhamis, K. M., Alseraye, F. S., Alshehri, F. A. A., Bosaid, R. B., Alahmari, R. S., Alohali, I. S., & Alotaibi, A. S. (2026) · Journal of Nature and Science of Medicine · doi:10.4103/jnsm.jnsm_74_25
Hager, D. N., Zhu, Y., Sohn, I., Stubblefield, W. B., Streiff, M. B., Gaglani, M., Steingrub, J. S., Duggal, A., Felzer, J., O’ROURKE, M. E., et al. (2024) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiae502
COVID‐19: Neurology Perspective
Keyhanian, K., Umeton, R. P., Mohit, B., McNeilly, B., & Ghasemi, M. (2022) · Wiley eBooks · doi:10.1002/9781119789741.ch15
Monteiro, H., Neto, A., Kahn, R., Santos, G. S., Carmona, H. A., de Andrade, J. S. D., & Castro, M. (2023) · medRxiv · doi:10.1101/2023.06.06.23291015 · Cited by 10
The cost–benefit and ethics of Covid-19 vaccine mandates in New Zealand
Lally, M. (2026) · Bioethics News · doi:10.1007/s40592-026-00284-3
Seroepidemiology of emerging viruses in Bolivia
Jordan, L. I. (2023) · theses.fr (ABES) · doi:10.70675/1070f335z49aaz4d85zb796z713dd35bc6fc
Deng, Z., Dunn, A. W., Sun, D. Q., & Shi, D. (2026) · Applied Physics Reviews · doi:10.1063/5.0342617 · Cited by 1
mRNA based vaccines as an alternative to conventional vaccine approaches
Zubda-tul, H., & Muhammad, Q. (2022) · Open Journal of Environmental Biology · doi:10.17352/ojeb.000026
Booster vaccination against the SARS-CoV-2: mechanisms and efficiency
Berns, S. A., Веремеев, А. В., Savicheva, A. A., Gorshkov, A. Y., & Drapkina, O. M. (2024) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2023-3820
A Rare Presentation of A Unilateral Bell’s Palsy Following mRNA COVID-19 Vaccine
Benhoummad, O., Rochd, S., Yafi, M., Rochdi, Y., & Raji, A. (2022) · European Journal of Medical and Health Sciences · doi:10.24018/ejmed.2022.4.6.1413
When Should Fractional-Dose Vaccines Be Used?Preprint
de Véricourt, F., Gallien, J., & Ghosh, N. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4751438
Makino, H., Fukuhara, S., Okinaka, K., Shibata, M., Hattori, D., Sasaki, H., Higashiyama, R. I., Iwaki, N., Munakata, W., Yagishita, S., et al. (2025) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaf207
Longitudinal proteomic and autoantibody signatures after mRNA vaccination in healthy individuals
Chazarin, B., Bhat, A., Sundararaman, N., Liu, Y., Gajewski, J., Lindemann, A.-S., Budde, P. I., Zucht, H., Joung, S. Y., Ebinger, J. E., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127888
The Good Life as a Constraint on Longevity Science
Farrelly, C. (2026) · Oxford University Press eBooks · doi:10.1093/9780197830062.003.0010
Merling, M., Williams, A., Mahfooz, N. S., Ruane-Foster, M., Smith, J., Jahnes, J., Ayers, L., Bazan, J., Norris, A., Turner, A., et al. (2023) · medRxiv · doi:10.1101/2023.01.30.23285195
“Since interrupting the Spike:ACE2 interaction was the goal of now-approved vaccines (32, 33), 103 and remains a goal of potential COVID therapies (34, 35), the continual emergence of new CoV2 104”
BackgroundAnsari, F., Salehi‐Pourmehr, H., Pashazadeh, F., Mahdavi, N., Atayi, M., Armand, N., & Pourjafar, H. (2025) · Current Nanoscience · doi:10.2174/0115734137365213250612113303
Kushima, H., Ishii, H., Kinoshita, Y., Koide, Y., Komiya, Y., Kato, J., Umehara, M., Sakata, M., Miyazaki, M., & Ikuta, M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11185388 · Cited by 1
“The mRNA vaccines developed against this background have been reported to be highly effective in preventing the onset and severity of COVID-19 with two to three or more vaccinations, and these vaccines have been recommended internationally as a key weapon in the fight against COVID-19 [2,3].”
BackgroundPopulational analysis of the immunoglobulin G response to different COVID-19 vaccines in BrazilPreprint
Paula, N. M., Conzentino, M. S., Gonçalves, A. C. A., et al. (2022) · medRxiv · doi:10.1101/2022.09.28.22280449
“Clinical studies involving the vaccines in use in Brazil reported efficacy against symptomatic infection after the 2nd shot of 95% for BNT162b2 (Polack et al. 2020), 62-67% ChAdOx1 (Voysey et al. 2021), 50-84% CoronaVac (Tanriover et al. 2021) https://www.bbc.com/news/world-latin-america-55642648 (Cerqueira-Silva et a…”
InfluentialFranco, J. E. M. (2021) · RiuNet (Universitat Politècnica de València) · doi:10.4995/thesis/10251/174883 · Cited by 1
das Chagas, R. R., Brasil, R. D. V., Freitas, H. R., de Carvalho, G. B., Gantus, M. A. V., Fortes, F. D. S. D. A., & Cardozo, S. V. (2025) · European Journal of Medical and Health Sciences · doi:10.24018/ejmed.2025.7.5.2380
“These associations align with prior evidence indicating that the absence of vaccination increases the risk of intense systemic and respiratory symptoms, which are potentially linked to heightened viral loads and unregulated inflammatory responses [1], [2].”
Neurological complications after covid-19 vaccination
Мухсиновна, Х. Х., Rashidova, N., & Salimjonov, J. (2023) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202312312113 · Cited by 2
Immunogenicity and Reactogenicity Following 2- and 3-Dose SARS-CoV-2 Vaccination in Persons With HIV
Teles, M. S., Lushniak, S., Chiang, T. P., et al. (2022) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000003112
Casado, J. L., Vizcarra, P., Martín-Hondarza, A., Gómez-Maldonado, S., Muedra-Sánchez, M., del Pino, J., Mirabella, I. G., Martín-Colmenarejo, S., Häemmerle, J., Fernández-Escribano, M., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1127379
“The introduction of vaccines has resulted in the prevention of SARS-CoV-2 infection and the management of disease severity (1, 2).”
BackgroundBene, A. D., D’Aniello, A., Mottola, S., Mazzarella, V., Cutolo, R., Campagna, E., Benedetti, R., Altucci, L., Cosconati, S., Maro, S. D., et al. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00032g
Cross-clade protection against human H5N1 isolates by a clade 2.3.4.4b HA mRNA vaccine in mice
Shichinohe, S., Li, Q., Tanaka, H., Anindita, J., Yoshimoto, S., Kaewaroon, N., Shimooka, M., Anzai, I., Akita, H., & Watanabe, T. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.129215
Peter Chew Formular for calculate Covid-19 Vaccine efficiencyPreprint
Chew, P. (2021) · Research Square · doi:10.21203/rs.3.rs-564631/v1
Bernal, J. A. L., Andrews, N., Gower, C., Stowe, J., Tessier, E., Simmons, R., & Ramsay, M. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciab881
Xiao, G., He, T., Zhang, B., et al. (2024) · International Journal of Public Health · doi:10.3389/ijph.2024.1605295
Modelling the impact of vaccination on SARS-CoV-2 transmission in EnglandPreprint
Derqui, N., Mishra, S., Hinsley, W. R., Bhatt, S., & Laydon, D. J. (2024) · medRxiv · doi:10.1101/2024.09.06.24313210 · Cited by 1
Birtolo, L. I., Pietro, G. D., D’Ascenzio, F., Cuccuru, G., Fabris, E., Merlo, M., Andreis, A., Cameli, M., Improta, R., Campo, G. C., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4859906
A Bioorthogonal Desilylation System Potentiates mRNA Therapeutics in Tumors
Zhang, M., Wang, C., Xu, X., Ding, Z., Chen, J., Guo, Z., & Liu, Z. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.6c09548
Three-Dose Vaccination-Induced Immune Responses Protect Against SARS-CoV-2 Omicron BA.2Preprint
Zhou, R., Liu, N., Li, X., Peng, Q., Yiu, C.-K., Huang, H., Yang, D., Du, Z., Kwok, H., Au, K., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4123263
SARS-COV-2 and Other mRNA Vaccines
Jackson, N. (2022) · RNA technologies · doi:10.1007/978-3-031-08415-7_6
Leddin, E. M. (2022) · University of North Texas Digital Library (University of North Texas) · doi:10.12794/metadc1944361
Inzaule, S. C., Silva, R., Ford, N., Thwin, S. S., Jassat, W., Zumla, A. I., Doherty, M. C., Diaz, J., & Bertagnolio, S. (2026) · Medicine · doi:10.1097/md.0000000000049386
“[4] While COVID-19 vaccines have been widely administered, underrepresentation of PLHIV in clinical trials [5,6] limits our understanding of vaccine responses in this population.”
COVID-19: A Review of What You Should Know and Do to Keep Safe
Lokuruka, M. (2021) · African Journal of Food Agriculture Nutrition and Development · doi:10.18697/ajfand.101.20975
Sanjeev, A., Hannigan, C., Garrity, R., Kamalakkannan, D. S., Clendaniel, V., Mantri, M., Glass, Z., Kasiewicz, L. N., Leipheimer, J., Khan, Z., et al. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201722 · Cited by 1
Case series: Design, measures, and classic examples
Diab, R., Zeitoun, J., & Yaman, N. E. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-90391-2.00097-x
Lu, X., Hayashi, H., Ishikawa, E., Takeuchi, Y., Dychiao, J. V. T., Nakagami, H., & Yamasaki, S. (2023) · eLife · doi:10.7554/elife.89999.1
van der Pol, S., Beck, E. C., Westra, T. A., et al. (2026) · medRxiv · doi:10.64898/2026.02.18.26346561
COVID-19 in kidney transplant recipients; an Indian experience
Gouthami, B., Naik, N. D., Bennikal, M., et al. (2022) · Journal of Nephropathology · doi:10.34172/jnp.2022.17232
“Age 57 (46-68) 60 (50-67) 62 (52-69) 57 (29-83) 56 (4-66) 64 (55-68) 42.”
BackgroundSharmin, E., & Ahmed, S. F. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4639158
Relationship between Side Effects of BNT162b2 Inoculation and IgG Antibody Titers
Osumi, T., Shimizu, H., KOMURO, H., KAWADA, T., INOUE, A., Yasuhiro, K. I. K. O., Iwase, S., & Nishikawa, M. (2022) · Kansenshogaku zasshi · doi:10.11150/kansenshogakuzasshi.96.125
Dual pKa Lipid Nanoparticles for Lung‐tropic mRNA Delivery and pH‐Programmed Endosomal Escape
Lim, S. G., Lee, M., Wang, Y., Choi, E., Park, J. S., Park, K., Jeon, H., Kim, D., Lee, D., Lee, Y., et al. (2026) · Advanced Science · doi:10.1002/advs.77387
“Messenger RNA (mRNA)-containing lipid nanoparticles (LNPs) have delivered major clinical impact through COVID-19 vaccines [ 1, 2 ] and are expanding rapidly toward systemic gene therapy [ 3, 4 ].”
Advances and Challenges in Nanodelivery Systems for RNA Vaccines
Li, H., Zhao, Y., Yang, J., Guo, J., Cai, H., & Tong, A. (2026) · ACS Nano · doi:10.1021/acsnano.6c10327 · Cited by 2
Bando, T., Ikematsu, H., Kawai, N., et al. (2026) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2026.102953
Les virus au service de la santé : la vaccination
Tangy, F., & Tournier, J. (2022) · médecine/sciences · doi:10.1051/medsci/2022168
Cancer in COVID-19 Times – A Narrative Review of Guidelines and Recommendations
Gorzo, A., & Sur, D. G. (2021) · Journal of Medical and Radiation Oncology · doi:10.53011/jmro.2021.01.11
O Impacto da Covid-19 sobre a Guarda Compartilhada e os Efeitos da Alienação Parental
de Oliveira, A. M. X., da Silva, J. L., de Sousa, J. R. B., de Brito, M. V. T., Oliveira, R. R. S., de Freitas, S. A. N., Rodrigues, S. B. L., & Ferreira, F. D. F. (2021) · Uniedusul Editora eBooks · doi:10.51324/86010749.7
Past achievements and future perspectives of personalized vaccines and the role of dendritic cells
Larijani, M. S., Bavand, A., Moradi, L., & Ramezani, A. (2026) · Immunologic Research · doi:10.1007/s12026-026-09812-z
“The COVID-19 pandemic demonstrated that mRNA vaccines can be developed and manufactured rapidly on a large scale [ 87 , 88 ].”
Gold, M. J., Millar, D. G., Liu, J., Menon, H., Karpov, Y., Olsen, K., Oliveira, L. T., Dubé, C., Tran, C. W., Elford, A. R., et al. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.103076
Alshammari, A. D., Zafar, M., Alshabrami, F. K., & Alshammari, S. B. (2026) · Asian Journal of Pharmaceutical Research and Health Care · doi:10.4103/ajprhc.ajprhc_20_26
Síndrome de Hiper IgD: espectros clínicos, achados genéticos e condutas terapêuticas
Prado, A. I., Castro, F. F. M., Kalil, J., et al. (2020) · Arquivos de Asmas Alergia e Imunologia · doi:10.5935/2526-5393.20200049
Engineering a SARS-CoV-2 vaccine targeting the RBD cryptic-face via immunofocusingPreprint
Bruun, T. U. J., Do, J., Weidenbacher, P. A. B., & Kim, P. S. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.05.597541
T Cell Immune Responses against SARS-CoV-2 in the With Corona Era
Oh, J.-E. (2022) · Journal of Experimental & Biomedical Sciences/Biomedical Science Letters · doi:10.15616/bsl.2022.28.4.211
Developing PPE management tools for use in a pandemic
Edmondson, M. G., & Ramachandran, G. (2026) · Journal of Occupational and Environmental Hygiene · doi:10.1080/15459624.2026.2639995
Salehi, M., Darazam, I., Nematollahi, A., Alimohammadi, M., Pouya, S., Alimohammadi, R., Khajavirad, N., Porgoo, M., Sedghi, M., Sepahi, M., et al. (2023) · medRxiv · doi:10.1101/2023.11.01.23297898
Hammond, K., Bourdeau, F., Klein, M., Vinh, D. C., & Semret, M. (2024) · Journal of the Association of Medical Microbiology and Infectious Disease Canada · doi:10.3138/jammi-2024-0005
Abdelkhalek, A. F., & Daly, J. M. (2024) · Zoonotic Diseases · doi:10.3390/zoonoticdis4040021
Nanomaterials for Therapeutic Nucleic Acid Delivery
Du, S., Cheng, J. K. J., & Dong, Y. (2022) · Springer eBooks · doi:10.1007/978-981-16-1313-5_100-1
AbuBakr, N., Mubarak, R. T., Haggag, T., & Khaled, H. (2025) · Journal of Stomatology Oral and Maxillofacial Surgery · doi:10.1016/j.jormas.2025.102393
Unilateral idiopathic neuroretinitis following Pfizer-BioNTech COVID-19 vaccine: a case report
Bonnet, L. A., Ramachandran, N., Ah‐Chan, J., et al. (2023) · Ophthalmology Journal · doi:10.5603/oj.2023.0005
Chong-Valbuena, A., De-Jesús-María, I., Agurto-Ramírez, A., Gimeno, F. P., & García, M. M. M. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.05.015 · Cited by 1
“In our study, the incidence of AEs in healthcare personnel was higher after the second dose than with the first one, which coincides with the safety and efficacy findings for the BNT162b2 mRNA Covid-19 Vaccine [5].”
Rodriguez‐Watson, C., Ware, K., Eckert, J. C., et al. (2026) · Journal of Women s Health · doi:10.1177/15409996261444636
Tsoi, H., Ng, M. K.-W., Cai, J., Poon, R. W., Chan, B. P.-C., Chan, K., Tam, A. R., Chu, W.-M., Hung, I. F., & To, K. K. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4824990
Ateş, A. K. (2025) · Journal of Research in Pharmacy · doi:10.12991/jrespharm.1734697
(2000) · Time to knit · doi:10.1016/s2211-9698(21)44374-8
Truong, L. V., Nguyen, T. V., Trang, V. T. T., Le, T. T. T., Thum, C. C., Nguyen, D., Wong, Y. J., Jain, N., Binh, M. N. L. T., Anh, D. H., et al. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.128196
Interpretations of Studies on SARS-CoV-2 Vaccination and Post-acute COVID-19 Sequelae
Gonçalves, B. P., Olliaro, P., Horby, P., Merson, L., & Cowling, B. J. (2024) · Epidemiology · doi:10.1097/ede.0000000000001720 · Cited by 1
Jo, N., Hidaka, Y., Kikuchi, O., Fukahori, M., Sawada, T., Aoki, M., Yamamoto, M., Nagao, M., Morita, S., Nakajima, T., et al. (2022) · bioRxiv · doi:10.1101/2022.05.10.490700 · Cited by 2
“Notably, AEs have been more frequently observed after the second dose and with higher severity than after the first dose (14), which strongly suggested that AEs are a consequence of immunological memory induced by the adaptive immune system.”
BackgroundResultInfluentialMoya‐Salazar, J., Ciprian, L. Y., Rojas-Zumarán, V., et al. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1592019
“The Pfizer-BioNTech COVID-19 Vaccine (CONMIRNATY) has been one of the most accepted, safe, and available in most of the countries in the midst of 2021, which made it be one of the most used (3).”
Take Your Best Shot: Which SARS-CoV-2 Vaccine Should I Get?
Eckman, M. H., Powers‐Fletcher, M. V., Forrester, J. W., Fichtenbaum, C. J., Lofgren, R. P., & Smulian, A. G. (2021) · MDM Policy & Practice · doi:10.1177/23814683211031226
“In the case of the mRNA vaccine, we averaged data from both the BNT162b2 and mRNA1273 studies to describe the increasing vaccine efficacy over time during the first month.(4,5) For the mRNA vaccine strategy, patients are scheduled to receive two doses.”
BackgroundMethodResultInfluentialDevelopment of New Screening Methods for SARS CoV 2 and its Associated Developing Variations
Kumari, D., Mavi, A. K., Chaudhary, J. S., Kumar, M., Gupta, R. K., & Kumar, U. (2024) · Defence Life Science Journal · doi:10.14429/dlsj.9.19191
“The BNT162b2 immunization, according to Polack et al., prevents COVID-19 in people who are 16 years old and older with a 95 % efficacy rate and few serious adverse effects 14 .”
MethodScherer, D., Honrath, S., Kurmann, J., Klipp, A., Brigger, F., & Leroux, J. (2026) · Advanced NanoBiomed Research · doi:10.1002/anbr.70124
Vaccines for SARS coronavirus 2 and the new normal in vaccinology
Griffiths, P. D. (2021) · Reviews in Medical Virology · doi:10.1002/rmv.2229
Raeder, V., Boesl, F., Bremer, B., Breuer, A., Audebert, H. J., & Franke, C. (2026) · Digital Health · doi:10.1177/20552076261451372
Bignon, E., & Monari, A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821978-2.00101-x · Cited by 3
Poolchanuan, P., Tiacharoen, V., Dulsuk, A., Phunpang, R., Runcharoen, C., Boonprakob, T., Hemtong, O., Chowplijit, S., Chuapaknam, V., Siripoon, T., et al. (2026) · Scientific Reports · doi:10.1038/s41598-025-33388-7 · Cited by 2
“Factors such as the extended dosing interval of mRNA vaccines, their adjuvant properties, and the potential for continued affinity maturation of RBD-targeting antibodies may contribute to these responses 55–57 .”
Kurihara, C., Greco, D. B., Dhai, A., & Saio, T. (2025) · Springer eBooks · doi:10.1007/978-981-96-9294-1_11
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.